Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | F13A1 | P00488 | 1/20 | 0.35 |
| ▸ | TGM2 | P21980 | 1/20 | 0.35 |
| ▸ | TGM1 | P22735 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3781362 | 0.86 | SMN1; SMN2 (0.42) | PDE4BSMN1; SMN2NPC1RAB9APARP1 | |
| SCHEMBL3780136 | 0.84 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL1043277 | 0.79 | NPC1 (0.39) | SMN1; SMN2NPC1RAB9A | |
| SCHEMBL3788783 | 0.79 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL6166147 | 0.75 | SMN1; SMN2 (0.47) | PDE4BSMN1; SMN2NPC1RAB9APARP1 | |
| SCHEMBL1042956 | 0.74 | NPC1 (0.38) | SMN1; SMN2NPC1RAB9A | |
| SCHEMBL13567846 | 0.73 | SMN1; SMN2 (0.52) | PDE4BSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL18592896 | 0.72 | SMN1; SMN2 (0.53) | PDE4BSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL10130022 | 0.72 | SMN1; SMN2 (0.48) | PDE4BSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL31617924 | 0.70 | NAMPT (0.56) | PDE4BSMN1; SMN2NPC1RAB9ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309341-B2 | 2-mercaptocyclopentanecarboxylic acid compounds, a process for their preparation and pharmaceutical compositions containing them | Les Laboratories Server (FR) | 2012-11-13 | — | — | US | disclosed |
| US-20100330064-A1 | 2-mercaptocyclopentanecarboxylic acid compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100330064-A1 | 2-mercaptocyclopentanecarboxylic acid compounds, a process for their preparation and pharmaceutical compositions containing them | CYP2B6, CYP2A6, MC5R | PDE4B 2392/4885SMN1; SMN2 3384/4885NPC1 1976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.